Hepatitis B News and Research

Latest Hepatitis B News and Research

Scientists discover how ovarian tumors evade immune system

Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked.

1 Dec 2008

Etanercept found to be ineffective in treating alcoholic hepatitis

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.

1 Dec 2008

Childhood vaccines cause financial burden to many health care providers

The costs that health care providers are charged and reimbursed for childhood vaccines vary widely, and the high cost of some immunizations is leading to significant financial strain for some physicians, according to a pair of new studies from the University of Michigan Health System.

1 Dec 2008

Antibiotics causing most drug-induced liver injury

Antibiotics are the single largest class of agents that cause idiosyncratic drug-induced liver injury (DILI), reports a new study in Gastroenterology, an official journal of the American Gastroenterological Association (AGA) Institute.

1 Dec 2008

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor.

1 Dec 2008

Liver disease tackled with dedicated unit at Imperial College London

Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.

1 Dec 2008

Research identifies cell receptor as target for anti-inflammatory immune response

Cell reception. By comparing normal mice (left) with mice that are genetically engineered to lack certain receptors in their spleen (right), scientists have shown SIGNR1 receptors (blue) are required to facilitate an anti-inflammatory action.

28 Nov 2008

Peregrine Pharmaceuticals awarded U.S. patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

25 Nov 2008

Researchers develop new strategy for broad spectrum anti-viral drugs

Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.

24 Nov 2008

Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer

Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer.

24 Nov 2008

FDA approves GSK's Promacta (Eltrombopag)

GlaxoSmithKline has announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

20 Nov 2008

Common cold virus originated in birds

A virus that causes cold-like symptoms in humans originated in birds and may have crossed the species barrier around 200 years ago, according to an article published in the December issue of the Journal of General Virology.

20 Nov 2008

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

Adults need vaccines to protect from preventable diseases, say medical societies

The American College of Physicians (ACP) and the Infectious Diseases Society of America (IDSA) have released a joint statement on the importance of adult vaccination against an increasing number of vaccine-preventable diseases.

19 Nov 2008

A cost-effectiveness analysis of Canada's supervised injection site

A cost-effectiveness analysis of Insite, Canada's only supervised safe injection site in Vancouver, concludes that it results in $14 million in savings and health gains of 920 life-years over 10 years.

17 Nov 2008

Governments urged to take broader perspective when considering whether to fund vaccines

Including quality-of-life impacts in assessments of national vaccination programs would lead to many benefits, including improved productivity and less sick leave for parents, according to an editorial co-authored by a University of New South Wales (UNSW) researcher, that has appeared in the Lancet Infectious Diseases.

17 Nov 2008

Calls for a more flexible approach to vaccine funding

Governments should take a broader perspective - including quality-of-life impacts - when considering whether to fund vaccines, according to a paper from the University of New South Wales (UNSW).

11 Nov 2008

One in ten patients harmed in Australian hospitals

Researchers from the University of New South Wales (UNSW) plan to tackle underlying problems in Australia's health system which harm in one in ten hospital patients each year.

10 Nov 2008

Caesarean sections do not reduce hepatitis C transmission

Planned Caesarean sections do not help to reduce the chances of a pregnant mother with Hepatitis C (HCV) transmitting the infection to her unborn baby, according to new scientific findings by the National Maternity Hospital in Dublin and University College Dublin.

7 Nov 2008

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

4 Nov 2008